<DOC>
	<DOC>NCT00396604</DOC>
	<brief_summary>The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD. All patients will receive 1 day of treatment with each of the following: indacaterol 150 µg, once- indacaterol 300 µg, indacaterol 600 µg, placebo, and formoterol. Each treatment day will be followed by a washout-period of 1 week.</brief_summary>
	<brief_title>Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<criteria>Male and females aged 4075 years with COPD and symptoms such as cough, sputum production, and shortness of breath. Smoking history of at least 10 pack years FEV1 less than 65% of the predicted normal value and at least 0.75 L Prebronchodilator FEV1/FVC less than 70% A history of asthma or COPD diagnosis before the age of 40 Hospitalization for COPD exacerbation within the previous 6 weeks Respiratory tract infection within 6 weeks Use of longterm oxygen therapy Diabetes type I or uncontrolled diabetes type II Clinically relevant laboratory abnormality or clinically significant condition Corrected QT interval (QTc) above 430 ms for males and 450 ms for females, or a history of QTc prolongation. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>long acting beta agonist</keyword>
</DOC>